Association between smoking and recurrence of venous thromboembolism and bleeding in elderly patients with past acute venous thromboembolism. by Carruzzo, P. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but does not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Association between smoking and recurrence of venous 
thromboembolism and bleeding in elderly patients with past acute 
venous thromboembolism. 
Authors: Carruzzo P, Méan M, Limacher A, Aujesky D, Cornuz J, Clair C 
Journal: Thrombosis research 
Year: 2016 Feb 
Volume: 138 
Pages: 74-9 
DOI: 10.1016/j.thromres.2015.11.034 
 
Philippe Carruzzo, Article SWITCO65+ 
 
 
Page 1 
 
  
Association between smoking and recurrence of venous 
thoromboembolism and bleeding in elderly patients with past 
acute venous thromboembolism 
 
Authors: 
Philippe Carruzzo, MD1; Marie Méan, MD2,4; Andreas Limacher, PhD, MAS, 
MSc3; Drahomir Aujesky, MD, MSc2 ; Jacques Cornuz, MD, MPH1; Carole Clair, 
MD, MSc1 
Author Affiliations: 
1Department of Ambulatory Care and Community Medicine, University of 
Lausanne, Lausanne (Drs. Carruzzo, Clair, and Cornuz); 2Department of 
General Internal Medicine, Bern University Hospital, Bern (Drs Méan, and 
Aujesky); 3Clinical Trials Unit Bern, Department of Clinical Research, and 
Institute of Social and Preventive Medicine, University of Bern, Bern (Dr. 
Limacher); 4Department of Internal Medicine, University hospital, Lausanne 
(Dr Méan) 
Corresponding author: 
Philippe Carruzzo, MD 
Policlinique Médicale Universitaire 
Rue du Bugnon 44 
1005 Lausanne 
Switzerland 
Email: philippe.carruzzo@unil.ch 
Phone: 0041 76 822 41 92 
Fax : 0041 314 61 06 
Number of references: 28 
Number of tables: 3 (max 8) 
Word count of the abstract: 249 
Word count of the text: 2624 (max 4000) 
Philippe Carruzzo, Article SWITCO65+ 
 
 
Page 2 
 
  
Key words: venous thromboembolism, recurrence, hemorrhage, smoking, 
aged  
Philippe Carruzzo, Article SWITCO65+ 
 
 
Page 3 
 
  
 
Abstract 
Background: While the association between smoking and arterial cardiovascular events 
has been well established, the association between smoking and venous 
thromboembolism (VTE) remains controversial.  
Objectives: To assess the association between smoking and the risk of recurrent VTE and 
bleeding in patients who have experienced acute VTE. 
Patients/Methods: This study is part of a prospective Swiss multicenter cohort that 
included patients aged ≥65 years with acute VTE. Three groups were defined according to 
smoking status: never, former and current smokers. The primary outcome was the time to 
a first symptomatic, objectively confirmed VTE recurrence. Secondary outcomes were the 
time to a first major and clinically relevant non-major bleeding. Associations between 
smoking status and outcomes were analysed using proportional hazard models for the 
subdistribution of a competing risk of death. 
Results: Among 988 analysed patients, 509 (52%) had never smoked, 403 (41%) were 
former smokers, and 76 (8%) current smokers. After a median follow-up of 29.6 months, 
we observed a VTE recurrence rate of 4.9 (95% confidence interval [CI] 3.7-6.4) per 100 
patient-years for never smokers, 6.6 (95%CI 5.1-8.6) for former smokers, and 5.2 (95%CI 
2.6-10.5) for current smokers. Compared to never smokers, we found no association 
between current smoking and VTE recurrence (adjusted sub-hazard ratio [SHR] 1.05, 
95%CI 0.49-2.28), major bleeding (adjusted SHR 0.59, 95%CI 0.25-1.39), and clinically 
relevant non-major bleeding (adjusted SHR 1.21, 95%CI 0.73-2.02). 
Conclusions: In this multicentre prospective cohort study, we found no association 
between smoking status and VTE recurrence or bleeding in elderly patients with VTE. 
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Introduction 
 
Venous thromboembolism (VTE), defined as deep vein thrombosis (DVT) and/or 
pulmonary embolism (PE), is a common disease[1]. The incidence of VTE increases with 
age, rising from <1 case per 1,000 person-years in persons aged <50 years to more than 6 
cases per 1,000 person-years in persons aged >80 years [2-6]. Overall, 60 % of VTE events 
occur in persons aged ≥65 years [1, 2, 7]. 
Several factors induced by smoking could promote the formation of a clot and the 
subsequent VTE. These mechanisms were often studied in researches on atherosclerosis, 
and smoking shares common biological consequences on the venous system. Smoking 
causes endothelial damage that can lead to a reduced capacity for dilatation (by a 
decreased activity of nitrous oxide) and increased vessel contraction (by stimulation of 
the release of catecholamines) [8-11]. This endothelial damage can lead to pro-
thrombotic and pro-inflammatory states with an increased production of cytokines 
including IL-6, IL1B and TNFα [8-11]. Those cytokines play major regulatory roles in the 
hepatic synthesis of acute phase proteins, including fibrinogen. As IL-6 appears to be the 
principal procoagulant cytokine in humans, it could be an important link to VTE [11, 12]. 
Moreover, there is a clear dose-effect relationship between number of cigarettes smoked 
per day and raised plasma fibrinogen concentration and conversely a reduction of it with 
smoking cessation [13]. 
The association between smoking and VTE remains controversial. While a meta-
analysis reported no statistically significant relationship between smoking and first VTE 
(odds ratio [OR] 1.18, 95% confidence interval [CI] 0.95-1.46) [14], a recent meta-analysis 
demonstrated that cigarette smoking was associated with a slightly increased risk for first 
VTE (pooled relative risk 1.23, 95% CI 1.14–1.33) in current smokers compared with never 
smokers [15].  
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Smoking interacts directly with the metabolism of vitamin K antagonists by 
increasing the required dosage to achieve and maintain a therapeutic international 
normalized ratio [16], potentially increasing the risk of VTE recurrence. 
Pathophysiologically, smoking may increase the clearance of warfarin and in this way 
reduce its anticoagulant effect. Therefore, smoking cessation or a decrease in smoking 
may lead to overanticoagulation and an increased risk of bleeding. 
Evidence suggests that elderly patients who have experienced an acute VTE may 
have a higher risk of VTE recurrence, bleeding, and death than younger patients [2, 7]. 
Given that the elderly are a rapidly growing population segment in Western societies and 
almost half of the elderly population is or has been exposed to smoking [17], it is of 
interest to examine the possible association between smoking and VTE recurrence and 
bleeding in this population. In a prospective multicenter cohort study, we aimed to assess 
the association between smoking status and the risk of recurrent VTE and bleeding in 
elderly patients with acute VTE. 
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Methods 
 
Cohort sample 
The study was conducted between September 2, 2009 and December 6 2013 as part of 
Swiss Cohort of Elderly Patients with Venous Thromboembolism (SWITCO65+), a 
prospective, multicenter cohort study that assessed long-term medical outcomes in 
elderly patients with acute VTE from all five university and four high-volume non-
university hospitals in Switzerland.  Consecutive patients aged ≥65 years with acute, 
objectively confirmed symptomatic VTE were prospectively identified in the inpatient and 
outpatient services of all participating study sites. Exclusion criteria were catheter-related 
thrombosis, insufficient German or French-speaking ability, no follow-up possible (i.e., 
terminal illness), an inability to provide informed consent (i.e., severe dementia), or 
previous enrollment in the cohort. The detailed methodology of the SWITCO65+ cohort 
has been described elsewhere [2]. The study has been approved by the Institutional 
Review Board at each participating center. For the present study, we excluded patients 
with missing information about their smoking status. 
 
Baseline data collection 
For all enrolled patients, trained study nurses prospectively collected information 
about baseline demographics (age, gender, insurance status, living status, and educational 
level), comorbid conditions (active cancer, hepatic, cardiac, lung, renal, and 
cerebrovascular disease, and history of major bleeding), traditional cardiovascular risk 
factors (arterial hypertension, diabetes mellitus, hypercholesterolemia, body mass index, 
physical activity level), risk factors for VTE (active cancer, recent immobilization, major 
surgery, estrogen therapy), type and localization  of the index VTE, VTE-related 
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treatments (oral and parenteral anticoagulants), and concomitant antiplatelet/non-
steroidal anti-inflammatory drug therapy using standardized data collection forms. 
Smoking habits, including self-reported smoking status, the average number of 
cigarettes smoked per day and years of smoking were assessed. We defined three 
possible smoking statuses: current smokers (i.e. patients reporting smoking ≥1 cigarette 
per day at the time of the interview), former smokers (defined as smokers who had quit 
for >6 months) and never smokers. Current and former smokers were classified into three 
subgroups according to the number of pack-years smoked (defined as the number of 
packs of cigarettes smoked per day multiplied by the duration of smoking in years ): ≤20, 
21-40, and >40 pack-years. 
 
Study outcomes 
The primary outcome was the time to the recurrence of symptomatic, objectively 
confirmed VTE during follow-up, defined as new or recurrent PE or DVT based on 
previously published criteria [18, 19]. We defined recurrent symptomatic VTE as acute 
chest pain, new or worsening dyspnea or cough, acute hemoptysis, or syncope coupled 
with an objective diagnosis of pulmonary embolism based on spiral computed 
tomography, pulmonary angiography, or autopsy, or a new unilateral leg pain or swelling 
coupled with an objective diagnosis of deep vein thrombosis based on ultrasonography or 
contrast venography. 
The secondary outcome was the time to a first bleeding event. We defined major 
bleeding as fatal bleeding, symptomatic bleeding in a critical organ (intracranial, intra-
spinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with 
compartment syndrome), bleeding with a reduction of hemoglobin ≥20 g/l, or bleeding 
leading to the transfusion of 2 units of packed red blood cells or more [2, 20]. Non-major 
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bleeding was defined as bleeding leading to a medical consultation or a visit to an 
emergency center, without fulfilling the criteria for major bleeding [2]. 
Follow-up included one telephone interview and two surveillance, face-to-face 
evaluations during the first year of study participation and then semi-annual contacts, 
alternating between face-to-face evaluations (clinic visits or home visits in house-bound 
patients) and telephone calls as well as periodic reviews of the patient’s hospital chart. 
During each visit/contact, study nurses interviewed patients to obtain information about 
the date and type of clinical events (recurrent VTE, bleeding, and death). If a clinical event 
had occurred, this information was complemented by reviewing medical charts and 
interviewing patients’ primary care physicians and family members. We assessed 
outcomes using patient or proxy interviews, interview of the patient’s primary care 
physician, and/or hospital chart review. A committee of three blinded clinical experts 
adjudicated all outcomes and classified the cause of all deaths as definitely due to PE, 
possibly due to PE, due to major bleeding, or due to another cause. Final classification was 
made on the basis of the full consensus of this committee. 
 
Statistical analysis 
We compared baseline and outcome characteristics of never, current, and former 
smokers using chi-squared test for categorical variables and non-parametric Kruskal-
Wallis test for continuous variables. Smoking characteristics of current and former 
smokers were compared using chi-squared and Wilcoxon rank-sum test as appropriate. 
We calculated the incidence rate of a first VTE recurrence in each group and compared 
incidences among groups using the incidence rate ratio. We estimated the cumulative 
incidence of a first VTE recurrence by the Kaplan-Meier method and compared survivor 
functions across groups of patients with different smoking status and the quantity of 
pack-years smoked by the logrank test.  
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We compared the percentage of time spent within one of three specified INR 
ranges (<2.0, 2.0-3.0, >3.0) across different smoking levels by analysis of variance 
(ANOVA), excluding the first seven treatment days and patients with no or only one INR 
measurement. 
Associations between smoking status and the time to the first VTE recurrence were 
assessed by competing risk regression accounting for death as a competing event, 
according to the method of Fine and Gray (1999) [21]. The method yields sub-hazard 
ratios (SHR) with corresponding 95% confidence intervals (CIs). Adjustments were done 
for age and gender and for variables associated with VTE recurrence, including prior VTE, 
active cancer, overt PE, and provoked VTE (defined as the presence of immobilization, 
major surgery, or current estrogen therapy during the last three months). For bleeding, 
adjustments were done for age and gender and for variables known to be associated with 
a higher bleeding risk, including chronic renal disease or or a creatinine clearance 
<30ml/min., history of major bleeding, anemia, and concomitant antiplatelet treatment 
[22-25]. We adjusted all analyses for periods of anticoagulation treatment as a time-
varying covariate. All analyses were done using Stata 13 (Stata Corporation, College 
Station, Texas). 
 
Results 
Of the 1003 patients enrolled in the cohort, 15 were excluded who did not allow 
use of their data (n=8), withdrew early (n=4), or missed information about smoking status 
(n=3). Therefore, the final study sample comprised 988 patients of whom 509 (52%) had 
never smoked, 403 (41%) were former smokers and 76 (8%) current smokers. The median 
follow-up duration was 29.6 months (IQR 18.8-36.2). 
Patient baseline characteristics are described in table 1. Former and current 
smokers reported a median of 16 and 30 pack-years, respectively. Never smokers were 
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more likely to be women and older than current and former smokers. Not surprisingly, 
current and former smokers were more likely to have lung disease and coronary heart 
disease and to receive concomitant antiplatelet therapy than never smokers. Finally, 
never smokers were more likely to receive vitamin K antagonists. 
Overall, 204 patients (20%) died during follow-up and 120 (12%) had recurrent 
VTE (table 2). VTE recurrence did not vary by smoking status. Furthermore, 131 patients 
(13%) had major and 199 (20%) non-major bleeding events during the follow-up. Again, 
bleeding did not differ by smoking status. 
 
Table 2 shows the incidence rate and incidence rate ratio (IRR) of VTE recurrence and 
major and non-major bleeding events for the three categories of smokers. Generally, 
compared with never smokers, current smokers tended to have a somewhat higher 
incidence rate of VTE recurrence (IRR 1.1 95% CI 0.4-2.8) and non-major bleeding events 
(IRR 1.2 95% CI 0.7-2.0) but a lower incidence of major bleeding events (IRR 0.7 95% CI 
0.2-1.5). 
After adjustment, current smokers did not have a statistically significantly 
increased risk of VTE recurrence compared with never smokers (adjusted SHR 1.05 95% CI 
0.49-2.28). Similarly, there was no statistically significant association between active 
smoking and major (adjusted SHR 0.59 95% CI 0.25-1.39) and non-major bleeding events 
(adjusted SHR 1.21 95% CI 0.73-2.02). We did not observe a statistically significant 
association between former smoking status and VTE recurrence or bleeding events. 
Moreover, we found no dose-response relationship between the number of pack-years 
and VTE recurrence in current and former smokers (data not shown). In patients who 
received treatment with vitamin K antagonists, the percentage of time spent in the 
therapeutic range did not vary by smoking status (data not shown). 
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Discussion 
 
In this prospective cohort of elderly patients with VTE, the incidence of recurrent 
VTE and bleeding did not vary by smoking status. We found no dose-response relationship 
between the number of pack-years smoked and VTE recurrence. After adjustment, 
smoking status was neither associated with recurrent VTE nor with bleeding. 
In the present study, the prevalence of active smoking (8%) was similar to that 
observed in the general Swiss population aged 65 years or older [26] but former smokers 
were over represented in this cohort (41% vs 33.3% for 65-74 years old and 26.7% for ≥75 
years old in the general Swiss population).  
While the relationship between smoking and the first VTE has been well studied, 
very few studies have examined the relationship between smoking status and recurrent 
VTE. A cross-sectional study on the impact of cardiovascular risk factor on the risk of 
recurrent VTE reported no statistically significant association between cigarette smoking 
and recurrence of VTE (hazard ratio [HR] 1.20, 95%CI 0.88-1.52) [27]. In this study of 
younger patients (mean age 43.5 years), the authors did not differentiate current smokers 
from former smokers and compared ever smokers (current and former smokers) to never 
smokers.  The reason why smoking seems to be associated with a first VTE but not with 
recurrent VTE remains unclear. However, after a first VTE event, smokers might reduce 
their cigarette consumption or make quit attempts, thus decreasing the risk of recurrent 
VTE. This might partly explain why smoking was not associated with an increased risk of 
VTE recurrence in the present study. 
 
Regarding the possible dose-response relationship between smoking and VTE recurrence, 
we found no association between number of pack-years and VTE recurrence. A large 
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population-based case-control study showed a clear dose-dependent, reversible 
association of smoking and the risk of a first VTE [28]. The limited number of smokers in 
our study (n=76) might explain the absence of significant dose-response relationship.  
In this cohort, smoking was not associated with an increased risk of major and 
clinically relevant non-major bleeding. Evidence suggests that smokers may need higher 
doses of warfarin per week than nonsmokers [16]. Smoking not only increases the dosage 
of required oral anticoagulant, but the variation of smoking amount or frequency may 
have an influence on the stability of anticoagulation making it difficult to maintain the 
anticoagulation in the therapeutic range.  However, to our knowledge, there are no 
studies exploring the effect of smoking on the quality of oral anticoagulation. In our study, 
we found no difference in the percentage of time in the therapeutic range between 
smokers, former smokers, and never smokers. This may be due again to the limited 
sample of smokers. This study contains no information on quitting smoking, variation of 
consumption of cigarettes during the week or increased or decreased mean consumption 
of cigarettes.  
The main strength of the study is that it prospectively followed patients over 3 years. It is 
the first prospective study examining the association between smoking status and 
outcomes in patients with VTE.  
Our study has potential limitations. First, the study sample may not reflect the full 
prognostic spectrum of patients with VTE because analyzed patients were younger and 
more likely to be men than excluded patients. Thus we cannot rule out the possibility that 
the association between smoking status and bleeding and VTE recurrence would have 
been different in more severely ill patients. Second, an important limitation of this study 
is the small number of current smokers and the consequent lack of statistical power of 
our analysis. Moreover, the smoking status and number of cigarettes smoked a day were 
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self-reported by patients and might be underestimated. Finally, smoking status was only 
assessed at baseline and was not updated over follow-up (no information on initiation, 
cessation or relapse of smoking). However, we can assume that initiation of smoking in a 
population age > 65 years old is very unusual. Finally, our results are valid only for a 
Caucasian European population, given the relatively high socio-economical status of the 
population included and are not generalizable to other populations.  
 
In conclusion, we found no differences in anticoagulation quality in smokers, 
former smokers, and never smokers in this prospective cohort of elderly patients with 
VTE. Moreover, smoking status was not significantly associated with VTE recurrence or 
bleeding. This study investigated for the first time the impact of smoking in this 
population.  
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Tables 
Table 1:  Baseline characteristics of the patients, by smoking status 
 Current smokers 
n = 76 
Former smokers 
n = 403 
Never smokers 
n = 509 
P-value 
     
Socio-demographic     
Patient age, median (IQR)  74.0 (69.0; 79.0)  74.0 (69.0; 80.0)  76.0 (70.0; 82.0) 0.002 
Gender (female), n (%)     19 (25.0%)         123 (31%)        319 (63%)    <0.001  
High school graduate or 
more, n (%) 
    36 (47%)         189 (47%)        219 (43%)     0.474  
Living status, n (%)                                                           0.006  
living at home with 
spouse, partner, or 
family member 
    50 (66%)         281 (69%)        296 (58%)      
living at home alone     23 (30%)         113 (28%)        200 (39%)      
living in nursing home      3  (4%)           9  (2%)         12  (2%)      
Smoking characteristics     
Average number of 
cigarettes per day, median 
(IQR) 
 15.0  (7.0; 20.0)  20.0  (7.0; 25.0) n.a  
Years of smoking, median 
(IQR) 
 48.0 (30.0; 54.0)  20.5 (10.0; 38.3) n.a  
Cigarettes in pack-years, 
median (IQR) 
 30.0 (15.0; 55.0)  16.0  (5.0; 40.0) n.a  
Comorbidities / History of     
Chronic or acute lung 
disease, n (%) 
    21 (28%)          80 (20%)         53 (10%)    <0.001  
Coronary heart disease, n 
(%) 
    16 (21%)          91 (23%)         65 (13%)    <0.001  
Arterial hypertension, n (%)     48 (63%)         254 (63%)        334 (66%)     0.701  
Hypercholesterolemia, n (%)     28 (37%)         129 (32%)        145 (29%)     0.241  
Diabetes mellitus, n (%)     14 (18%)          74 (18%)         67 (13%)     0.080  
BMI, median (IQR)  26.0 (23.8; 29.8)  26.7 (24.1; 29.8)  26.8 (24.1; 30.0)  0.797  
Low physical activity, n (%)     26 (34%)         154 (38%)        187 (37%)     0.783  
Index VTE characteristics     
Type of thrombosis, n (%)                                         0.531  
 distal DVT only      6  (7.9%)          35  (8.7%)         39  (7.7%)      
 proximal DVT     23 (30.3%)          87 (21.6%)        113 (22.2%)      
 pulmonary embolism     47 (61.8%)         281 (69.7%)        357 (70.1%)      
Prior VTE, n (%)     18 (23.7%)         128 (31.8%)        136 (26.7%)     0.153  
Provoked index VTE*, n (%)     24 (31.6%)         128 (31.8%)        143 (28.1%)     0.458  
Immobilization during the 
last 3 months, n (%) 
    16 (21.1%)          98 (24.3%)        103 (20.2%)     0.329  
Major surgery during the 
last 3 months, n (%) 
    11 (14.5%)          65 (16.1%)         73 (14.3%)     0.747  
Current oestrogen therapy 
during the last 3 months, n 
     2  (2.6%)          12  (3.0%)         18  (3.5%)     0.849  
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(%) 
Active cancer requiring 
therapy, n (%) 
    15 (19.7%)          83 (20.6%)         79 (15.5%)     0.127  
Bleeding risk factors      
Anemia, n (%)     25 (33%)         177 (44%)        185 (36%)     0.093  
History of major bleeding, n 
(%) 
    10 (13%)          41 (10%)         50  (10%)     0.672  
Chronic renal disease or 
CrCl<30, n (%) 
    14 (18%)          92 (23%)         96 (19%)     0.303  
Concomitant antiplatelet 
therapy, n (%) 
    29 (38%)         143 (36%)        148 (29%)     0.065  
Type of initial parenteral AC, 
n (%) 
                                                          0.772  
LMWH     36 (47%)         193 (48%)        234 (46%)      
 UFH     26 (34%)         139 (35%)        167 (33%)      
 Fondaparinux     13 (17%)          58 (14%)         87 (17%)      
 Danaparoid      0  (0%)           1  (0.2%)          0  (0%)      
 None      1  (1%)          12  (3%)         21  (4%)      
Vitamin K antagonist, n (%)     61 (80%)         342 (85%)        455 (89%)     0.028  
     
N number, IQR interquartile range, n.a. non-applicable, VTE venous thromboembolism, DVT deep vein thrombosis, TIA 
transient ischaemic accident, CrCl creatinine clearance, AC anticoagulation  
Missings <=0.5% for every variable except for anemia (6.4%). 
*Defined as the presence of at least one out of three risk factors: immobilization, major surgery, or current oestrogen 
therapy during the last three months.  
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Table 2 Outcome data 
 Current smokers Former smokers Never smokers P-value 
  n=76 n=403 n=509   
Death during FU, n (%)      17  (22%)           89 (22%)            98 (19%)       0.536  
 
VTE recurrence 
    
VTE recurrence during FU, 
n (%) 
      8  (11%)           58 (15.1%)            54 (11%)       0.200  
Incidence rate per 100 
patient-years (95%-CI) 
5.2 (2.6-10.5) 6.6 (5.1-8.6) 4.9 (3.7-6.4)  
Incidence rate ratio (95%-
CI) 
1.1 (0.4-2.8) 1.4 (0.9-2.0) 1 (ref.)  
Type of VTE recurrence, n 
(%) 
                                                                  0.729  
 distal DVT only       1  (13%)            3  (5%)             5  (9%)        
 proximal DVT only        3  (38%)           16 (28%)            12 (22%)        
 pulmonary 
embolism 
      4  (50%)           39 (67%)            37 (69%)        
Under anticoagulant 
therapy at time of VTE 
recurrence*, n (%) 
      3  (38%)           17 (29%)            12 (22%)       0.540  
UFH       0 (.%)            2 (15%)             1 (11%)       0.774  
LMWH       0    ( .%)            1 (8%)             3 (33.3%)       0.149  
fondaparinux       0    ( .%)            1  (8%)             0  (0.0%)       0.402  
VKA       3 (100.0%)           14 (93%)            10 (91%)       0.858  
Days between index VTE 
and recurrence, median 
(IQR) 
 230 (105; 257)  505 (209; 799)  396 (191; 678)  0.320  
Bleeding      
Major bleeding     
Major bleeding during FU, 
n (%) 
      6   (8%)           59 (15%)            66 (13%)       0.271  
Incidence rate per 100 
patient-years (95%-CI) 
3.9 (1.8-8.8) 6.9 (5.3-8.9) 6.0 (4.7-7.6)  
Incidence rate ratio (95%-
CI) 
0.7 (0.2-1.5) 1.2 (0.8-1.7) 1 (ref.)  
Non-major bleeding     
Non-major bleeding 
during FU, n (%) 
     17  (22%)           85 (21%)            97 (19%)       0.659  
Incidence rate per 100 
patient-years (95%-CI) 
11.4 (7.1-18.3) 10.5 (8.5-12.9) 9.4 (7.7-11.4)  
Incidence rate ratio (95%-
CI) 
1.2 (0.7-2.0) 1.1 (0.8-1.5) 1 (ref.)  
n number, FU follow-up, VTE venous thromboembolism, DVT deep vein thrombosis, UFH unfractionated heparin, LMWH 
low molecular weight heparin, VKA vitamin K antagonist, IQR interquartile range 
*Multiple options possible. 
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Table 3 Association between smoking and risk of VTE recurrence and bleeding events 
  Current smokers 
n=76 
Former smokers 
n=403 
Never smokers 
n=509 
VTE recurrence       
Crude SHR (95%-CI) 1.04 (0.49 to 2.2) 1.35 (0.93 to 1.96) 1 (ref.) 
Adjusted* SHR (95%-CI) 1.05 (0.49 to 2.28) 1.33 (0.90 to 1.98) 1 (ref.) 
Bleeding    
Major bleeding       
Crude SHR (95%-CI) 0.61 (0.26 to 1.41) 1.14 (0.80 to 1.61) 1 (ref.) 
Adjusted SHR (95%-CI) 0.59 (0.25 to 1.39) 1.09 (0.76 to 1.55) 1 (ref.) 
Non-major bleeding       
Crude SHR (95%-CI) 1.22 (0.73 to 2.04) 1.10 (0.82 to 1.47) 1 (ref.) 
Adjusted SHR (95%-CI) 1.21 (0.73 to 2.02) 1.09 (0.81 to 1.47) 1 (ref.) 
*Adjusted for age, gender, for VTE: prior VTE, provoked VTE, active cancer, overt PE, for bleeding: chronic renal disease or 
CrCl<30ml/min, history of major bleeding, anemia, and concomitant antiplatelet treatment. 
 
 
